Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 554,017 shares, a growth of 75.3% from the March 31st total of 316,118 shares. Approximately 4.2% of the shares of the company are sold short. Based on an average daily trading volume, of 434,687 shares, the days-to-cover ratio is presently 1.3 days.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Monday, April 20th. Ascendiant Capital Markets dropped their price target on Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Finally, HC Wainwright dropped their price target on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Vivos Therapeutics presently has an average rating of “Hold” and an average target price of $2.58.

Insider Transactions at Vivos Therapeutics

In other news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The shares were purchased at an average price of $1.34 per share, for a total transaction of $1,813,857.50. Following the purchase, the insider directly owned 1,353,625 shares of the company’s stock, valued at $1,813,857.50. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of VVOS. Acorn Wealth Advisors LLC purchased a new position in shares of Vivos Therapeutics in the 4th quarter valued at approximately $30,000. XTX Topco Ltd purchased a new position in shares of Vivos Therapeutics in the 2nd quarter valued at approximately $65,000. B. Riley Wealth Advisors Inc. purchased a new position in shares of Vivos Therapeutics in the 2nd quarter valued at approximately $220,000. DRW Securities LLC grew its stake in shares of Vivos Therapeutics by 179.5% in the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares during the last quarter. Finally, Connective Capital Management LLC purchased a new position in shares of Vivos Therapeutics in the 3rd quarter valued at approximately $620,000. 26.35% of the stock is currently owned by hedge funds and other institutional investors.

Vivos Therapeutics Trading Up 2.5%

Shares of VVOS stock opened at $0.86 on Tuesday. The business’s 50 day moving average is $1.27 and its two-hundred day moving average is $1.87. Vivos Therapeutics has a twelve month low of $0.81 and a twelve month high of $7.95. The company has a market capitalization of $11.64 million, a P/E ratio of -0.42 and a beta of 6.93. The company has a current ratio of 0.24, a quick ratio of 0.24 and a debt-to-equity ratio of 3.31.

Vivos Therapeutics (NASDAQ:VVOS) last announced its earnings results on Wednesday, April 15th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.08). Vivos Therapeutics had a negative net margin of 121.37% and a negative return on equity of 849.22%. The company had revenue of $3.82 million during the quarter, compared to analysts’ expectations of $7.10 million. During the same quarter last year, the business posted ($2.22) earnings per share. Equities analysts forecast that Vivos Therapeutics will post -1.45 EPS for the current year.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.